Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

1.5K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.5K
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

2.9K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
2.9K
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.3K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.3K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

793
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
793
Peripherally and Centrally Acting Muscle Relaxants: A Comparison01:09

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

4.8K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.8K
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

1.6K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dreams and nightmares: Clinical aspects, management, and links to psychiatric disorders.

L'Encephale·2026
Same author

Family History and Solar Insolation in Bipolar I Disorder.

Acta psychiatrica Scandinavica·2026
Same author

Insomnia in neurological disorders: Prevalence, mechanisms, impact and treatment approaches.

Revue neurologique·2023
Same author

Validation of a data collection set for the psychiatric, addiction, sleep and chronobiological assessments of patients with depression: A Delphi study for the SoPsy-depression French national cohort.

L'Encephale·2022
Same author

Sleep quality of medical students and relationships with academic performances.

L'Encephale·2021
Same author

Use of immediate release melatonin in psychiatry: BMI impacts the daily-dose.

L'Encephale·2020
Same journal

Measuring antidepressant side effects in military personnel - Clinical validation of the French version of the UKU-SERS-Pat Scale: A comparative study of patient and clinician ratings.

L'Encephale·2026
Same journal

[Empowerment in addictology].

L'Encephale·2026
Same journal

Evaluation of the links between smoking and conspiracy mentality.

L'Encephale·2026
Same journal

Use of a relevance assessment tool in therapeutic residential care: A real world study.

L'Encephale·2026
Same journal

Prevalence and characteristics of domestic violence in a sample of adult psychiatric outpatients: A cross-sectional study.

L'Encephale·2026
Same journal

From representations to practice: how professionals describe supporting parents with psychiatric or somatic illness or disability.

L'Encephale·2026
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
14:55

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

14.3K

Does baclofen have antidepressant qualities?

P A Geoffroy1, B Rolland2

  • 1Inserm, UMR-S 1144, 75006 Paris, France; Service de psychiatrie adulte, pôle neurosciences, groupe hospitalier Saint-Louis-Lariboisière-Fernand Widal, AP-HP, 200, rue du Faubourg-Saint-Denis, 75475 Paris cedex 10, France; UMR-S 1144, université Paris Descartes, 75006 Paris, France; UMR-S 1144, université Paris Diderot, 75013 Paris, France; Fondation FondaMental, 94000 Créteil, France.

L'Encephale
|May 25, 2016
PubMed
Summary

No abstract available in PubMed .

Keywords:
AntidepressantBaclofenBipolar disordersDepressionManiaManic symptomsSwitching

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.3K
Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
07:51

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors

Published on: November 14, 2014

18.0K

Related Experiment Videos

Last Updated: Mar 20, 2026

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
14:55

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

14.3K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.3K
Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
07:51

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors

Published on: November 14, 2014

18.0K